Concepts (181)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Thrombolytic Therapy | 7 | 2019 | 2218 | 1.22 | Why? |
| Fibrinolytic Agents | 6 | 2021 | 1702 | 0.97 | Why? |
| Pulmonary Embolism | 10 | 2021 | 4775 | 0.95 | Why? |
| Venous Thromboembolism | 8 | 2021 | 4273 | 0.83 | Why? |
| Blood Coagulation | 6 | 2019 | 2768 | 0.81 | Why? |
| Adenovirus Vaccines | 1 | 2021 | 103 | 0.81 | Why? |
| Anticoagulants | 13 | 2021 | 9563 | 0.77 | Why? |
| Horner Syndrome | 1 | 2018 | 2 | 0.76 | Why? |
| Jugular Veins | 1 | 2018 | 52 | 0.71 | Why? |
| Catheterization, Swan-Ganz | 1 | 2017 | 30 | 0.70 | Why? |
| Venous Thrombosis | 8 | 2021 | 2739 | 0.67 | Why? |
| Thrombophilia | 2 | 2020 | 1935 | 0.64 | Why? |
| Pregnancy Complications, Cardiovascular | 1 | 2018 | 231 | 0.60 | Why? |
| Ultrasonography, Interventional | 2 | 2017 | 560 | 0.59 | Why? |
| Infertility | 1 | 2018 | 247 | 0.58 | Why? |
| Rheumatoid Factor | 1 | 2014 | 67 | 0.57 | Why? |
| Sinus Thrombosis, Intracranial | 1 | 2021 | 550 | 0.57 | Why? |
| Thrombosis | 7 | 2021 | 7504 | 0.56 | Why? |
| Tissue Plasminogen Activator | 2 | 2018 | 778 | 0.54 | Why? |
| Reproductive Techniques, Assisted | 1 | 2018 | 400 | 0.52 | Why? |
| Arterial Occlusive Diseases | 1 | 2018 | 363 | 0.51 | Why? |
| Thromboembolism | 3 | 2021 | 2101 | 0.51 | Why? |
| Catheterization, Central Venous | 1 | 2018 | 458 | 0.50 | Why? |
| Blood Coagulation Tests | 1 | 2018 | 855 | 0.50 | Why? |
| Fibrinolysis | 1 | 2018 | 521 | 0.49 | Why? |
| ABO Blood-Group System | 1 | 2021 | 995 | 0.45 | Why? |
| Registries | 2 | 2021 | 12327 | 0.42 | Why? |
| Atrial Fibrillation | 3 | 2019 | 2320 | 0.41 | Why? |
| Enoxaparin | 3 | 2021 | 1064 | 0.39 | Why? |
| Embolectomy | 2 | 2019 | 101 | 0.37 | Why? |
| Rivaroxaban | 3 | 2021 | 467 | 0.34 | Why? |
| Massachusetts | 2 | 2021 | 1279 | 0.31 | Why? |
| Hemorrhage | 6 | 2021 | 3013 | 0.29 | Why? |
| African Americans | 1 | 2020 | 3363 | 0.27 | Why? |
| Population Surveillance | 1 | 2021 | 4967 | 0.27 | Why? |
| Patient Care Team | 1 | 2017 | 3556 | 0.25 | Why? |
| Obesity | 2 | 2018 | 7388 | 0.21 | Why? |
| Platelet Aggregation Inhibitors | 3 | 2020 | 1671 | 0.20 | Why? |
| Recurrence | 3 | 2018 | 3675 | 0.20 | Why? |
| Device Removal | 2 | 2018 | 221 | 0.19 | Why? |
| Factor Xa | 1 | 2019 | 113 | 0.19 | Why? |
| Factor Xa Inhibitors | 2 | 2021 | 490 | 0.18 | Why? |
| Phlebography | 1 | 2018 | 65 | 0.18 | Why? |
| Ultrasonic Waves | 1 | 2018 | 32 | 0.18 | Why? |
| Ultrasonic Therapy | 1 | 2018 | 43 | 0.18 | Why? |
| Infusions, Intra-Arterial | 1 | 2017 | 36 | 0.18 | Why? |
| Factor VIII | 1 | 2020 | 229 | 0.17 | Why? |
| Treatment Outcome | 12 | 2021 | 51732 | 0.17 | Why? |
| Immunoglobulin M | 1 | 2014 | 9091 | 0.16 | Why? |
| Genetic Association Studies | 1 | 2020 | 559 | 0.16 | Why? |
| Vena Cava Filters | 1 | 2017 | 89 | 0.16 | Why? |
| Patient Selection | 3 | 2020 | 4560 | 0.15 | Why? |
| Blood Proteins | 1 | 2020 | 551 | 0.15 | Why? |
| Stroke | 1 | 2019 | 8839 | 0.15 | Why? |
| Cardiovascular Diseases | 1 | 2021 | 11497 | 0.15 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.15 | Why? |
| Catheterization | 1 | 2018 | 264 | 0.15 | Why? |
| Risk Factors | 12 | 2020 | 71621 | 0.14 | Why? |
| Central Venous Catheters | 1 | 2017 | 188 | 0.14 | Why? |
| Drug Administration Schedule | 2 | 2021 | 2324 | 0.14 | Why? |
| Warfarin | 1 | 2019 | 402 | 0.14 | Why? |
| Genetic Predisposition to Disease | 2 | 2020 | 4027 | 0.13 | Why? |
| Infusions, Intravenous | 1 | 2018 | 1224 | 0.13 | Why? |
| Pyridones | 1 | 2019 | 738 | 0.13 | Why? |
| Intracranial Hemorrhages | 2 | 2019 | 1170 | 0.13 | Why? |
| Humans | 34 | 2021 | 930598 | 0.12 | Why? |
| Anemia, Sickle Cell | 1 | 2020 | 546 | 0.12 | Why? |
| Pulmonary Medicine | 1 | 2019 | 706 | 0.12 | Why? |
| Lower Extremity | 1 | 2017 | 593 | 0.12 | Why? |
| United States | 7 | 2021 | 46150 | 0.11 | Why? |
| Patient Preference | 1 | 2018 | 750 | 0.11 | Why? |
| Hypertension, Pulmonary | 1 | 2019 | 970 | 0.10 | Why? |
| Aged | 13 | 2021 | 215776 | 0.10 | Why? |
| Endovascular Procedures | 1 | 2019 | 1302 | 0.10 | Why? |
| Atherosclerosis | 1 | 2017 | 768 | 0.10 | Why? |
| Female | 16 | 2021 | 380317 | 0.10 | Why? |
| Aspirin | 1 | 2017 | 1043 | 0.10 | Why? |
| Risk | 2 | 2018 | 5288 | 0.10 | Why? |
| Time Factors | 5 | 2020 | 31397 | 0.10 | Why? |
| Heart Ventricles | 1 | 2018 | 1139 | 0.09 | Why? |
| Recombinant Proteins | 1 | 2019 | 3786 | 0.09 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 1510 | 0.09 | Why? |
| Pyrazoles | 1 | 2019 | 1791 | 0.09 | Why? |
| Lupus Erythematosus, Systemic | 1 | 2020 | 1380 | 0.09 | Why? |
| Vascular Diseases | 1 | 2017 | 846 | 0.09 | Why? |
| Male | 15 | 2021 | 367725 | 0.09 | Why? |
| Computed Tomography Angiography | 1 | 2018 | 2153 | 0.09 | Why? |
| Clinical Decision-Making | 2 | 2019 | 3755 | 0.09 | Why? |
| Outpatients | 1 | 2021 | 3417 | 0.09 | Why? |
| Social Determinants of Health | 1 | 2020 | 1757 | 0.09 | Why? |
| Oxygen Inhalation Therapy | 1 | 2021 | 3629 | 0.08 | Why? |
| Phenotype | 1 | 2018 | 4037 | 0.08 | Why? |
| Consensus | 2 | 2019 | 6345 | 0.08 | Why? |
| Middle Aged | 13 | 2021 | 270681 | 0.08 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2020 | 3607 | 0.08 | Why? |
| Hospitalization | 4 | 2021 | 54280 | 0.08 | Why? |
| Extracorporeal Membrane Oxygenation | 2 | 2021 | 5002 | 0.07 | Why? |
| Renal Insufficiency, Chronic | 1 | 2020 | 2654 | 0.07 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.07 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.07 | Why? |
| Dementia | 1 | 2018 | 1861 | 0.07 | Why? |
| Healthcare Disparities | 2 | 2020 | 3893 | 0.07 | Why? |
| Adult | 9 | 2021 | 244371 | 0.07 | Why? |
| Wounds and Injuries | 1 | 2017 | 1708 | 0.07 | Why? |
| Iran | 3 | 2021 | 5467 | 0.07 | Why? |
| Cardiology | 1 | 2019 | 2873 | 0.07 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.06 | Why? |
| Clinical Trials as Topic | 2 | 2020 | 7330 | 0.06 | Why? |
| Predictive Value of Tests | 1 | 2018 | 9537 | 0.06 | Why? |
| Inpatients | 1 | 2019 | 5161 | 0.06 | Why? |
| Tomography, X-Ray Computed | 3 | 2019 | 25144 | 0.06 | Why? |
| Socioeconomic Factors | 1 | 2020 | 8495 | 0.06 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.06 | Why? |
| Intensive Care Units | 4 | 2021 | 29594 | 0.06 | Why? |
| Retrospective Studies | 3 | 2021 | 105322 | 0.05 | Why? |
| Prospective Studies | 4 | 2018 | 43301 | 0.05 | Why? |
| Attitude of Health Personnel | 1 | 2018 | 4741 | 0.05 | Why? |
| Glycosaminoglycans | 1 | 2020 | 140 | 0.05 | Why? |
| Extremities | 1 | 2021 | 179 | 0.05 | Why? |
| Antidotes | 1 | 2019 | 46 | 0.05 | Why? |
| Double-Blind Method | 2 | 2021 | 5988 | 0.05 | Why? |
| Pandemics | 5 | 2021 | 389249 | 0.05 | Why? |
| Practice Guidelines as Topic | 2 | 2020 | 15421 | 0.05 | Why? |
| Placebos | 1 | 2021 | 629 | 0.04 | Why? |
| Restraint, Physical | 1 | 2018 | 74 | 0.04 | Why? |
| Venous Insufficiency | 1 | 2017 | 22 | 0.04 | Why? |
| Drug and Narcotic Control | 1 | 2019 | 134 | 0.04 | Why? |
| Prevalence | 1 | 2020 | 25773 | 0.04 | Why? |
| Inflammation | 1 | 2020 | 13255 | 0.04 | Why? |
| American Heart Association | 1 | 2019 | 347 | 0.04 | Why? |
| Fluoroscopy | 1 | 2017 | 140 | 0.04 | Why? |
| International Normalized Ratio | 1 | 2019 | 300 | 0.04 | Why? |
| Constriction, Pathologic | 1 | 2017 | 212 | 0.04 | Why? |
| Leg | 1 | 2017 | 142 | 0.04 | Why? |
| Equipment Safety | 1 | 2017 | 167 | 0.04 | Why? |
| Pregnancy | 1 | 2018 | 23879 | 0.04 | Why? |
| Age Factors | 1 | 2017 | 21039 | 0.04 | Why? |
| Medication Therapy Management | 1 | 2019 | 312 | 0.04 | Why? |
| Drug Costs | 1 | 2019 | 313 | 0.04 | Why? |
| Acute Disease | 2 | 2018 | 6029 | 0.04 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 8811 | 0.04 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.04 | Why? |
| Aged, 80 and over | 4 | 2019 | 88759 | 0.04 | Why? |
| Ventricular Function, Right | 1 | 2018 | 388 | 0.04 | Why? |
| Prognosis | 1 | 2018 | 32490 | 0.03 | Why? |
| Accidental Falls | 1 | 2019 | 448 | 0.03 | Why? |
| Hemostasis | 1 | 2020 | 811 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2020 | 2437 | 0.03 | Why? |
| Myocardial Infarction | 2 | 2021 | 3361 | 0.03 | Why? |
| Ischemia | 1 | 2021 | 901 | 0.03 | Why? |
| Decision Support Techniques | 1 | 2019 | 903 | 0.03 | Why? |
| Medicare | 1 | 2019 | 1048 | 0.03 | Why? |
| Dose-Response Relationship, Drug | 1 | 2021 | 3776 | 0.03 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2021 | 10649 | 0.03 | Why? |
| Kaplan-Meier Estimate | 1 | 2021 | 4260 | 0.03 | Why? |
| Ventricular Dysfunction, Right | 1 | 2018 | 639 | 0.03 | Why? |
| Risk Assessment | 3 | 2019 | 25439 | 0.03 | Why? |
| Young Adult | 2 | 2018 | 93724 | 0.03 | Why? |
| Odds Ratio | 1 | 2021 | 5861 | 0.02 | Why? |
| Health Care Costs | 1 | 2017 | 1007 | 0.02 | Why? |
| Recovery of Function | 1 | 2018 | 2461 | 0.02 | Why? |
| Thrombocytopenia | 1 | 2021 | 2093 | 0.02 | Why? |
| Age Distribution | 1 | 2017 | 3567 | 0.02 | Why? |
| Cause of Death | 1 | 2021 | 4823 | 0.02 | Why? |
| Guidelines as Topic | 1 | 2018 | 2844 | 0.02 | Why? |
| Cohort Studies | 2 | 2021 | 36005 | 0.02 | Why? |
| Critical Illness | 2 | 2020 | 17281 | 0.02 | Why? |
| Echocardiography | 1 | 2018 | 3661 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2017 | 3228 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2017 | 7268 | 0.02 | Why? |
| Databases, Factual | 1 | 2019 | 6248 | 0.02 | Why? |
| Length of Stay | 1 | 2021 | 11042 | 0.02 | Why? |
| Chronic Disease | 1 | 2017 | 5139 | 0.01 | Why? |
| Europe | 1 | 2018 | 12702 | 0.01 | Why? |
| Anti-Inflammatory Agents | 1 | 2020 | 6153 | 0.01 | Why? |
| Critical Care | 1 | 2021 | 14081 | 0.01 | Why? |
| Hospital Mortality | 1 | 2021 | 22087 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2019 | 48226 | 0.01 | Why? |
| Animals | 1 | 2020 | 78931 | 0.01 | Why? |
| Neoplasms | 1 | 2018 | 17251 | 0.01 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.01 | Why? |
Piazza's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(181)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(161)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_